$TEVA news
The latest TEVA stock news: headlines, filings, AI summaries and sentiment for $TEVA, updated around the clock.
- NYSE Observes Veterans Day with Moment of Silence and Corporate Updates
- Teva Pharmaceutical Industries Outlines 2030 Revenue Targets for Innovative Medicines
- Kamada Ltd. Reports Strong Q3 2026 Results and Raises Full-Year Guidance
- Teva Pharmaceuticals Reports Improved Margins and Growth in Branded Therapies
- TEVA PHARMACEUTICAL INDUSTRIES LTD - 10-Q Filing
- Teva Pharmaceutical Industries Reports Q3 2026 Results with Raised Full-Year Guidance
- Teva Pharmaceutical Acquires U.S. Commercialization Rights for Samsung Bioepis Biosimilars
- TEVA PHARMACEUTICAL INDUSTRIES LTD - 8-K Filing
- Teva Pharmaceutical Raises Full-Year Outlook Following Strong Q3 Performance
- Key Corporate Earnings Scheduled Before Market Open on Tuesday
- Teva Pharmaceuticals Discontinues Phase 2 Emrusolmin Study for Multiple System Atrophy
- Wall Street Analyst Updates: CrowdStrike, Amazon, and Rivian Upgraded While Coinbase Downgraded
- Teva Pharmaceutical Industries Pivot to Branded Drugs Drives Significant Stock Growth
- TEVA PHARMACEUTICAL INDUSTRIES LTD - 8-K Filing
- Stocks Making Significant Moves Midday: T-Mobile, Verizon, AT&T, Crown Castle, Teva & More
- Teva Gains FDA Approval for Monthly Olanzapine Injection to Treat Schizophrenia
- Teva Receives FDA Approval for Monthly Schizophrenia Injection Weltruza
- Teva and Samsung Bioepis Partner on Up to Six Biosimilars
- Teva Receives FDA Approval for Biosimilar Version of Amgen's Xgeva
- Oppenheimer Initiates Coverage of Viatris and Teva with Outperform Ratings
- Teva Pharmaceutical Industries Achieves Investment-Grade Ratings and Outlines Growth Strategy
- Teva CEO Outlines Biopharma Strategy and $700M Cost-Saving Plan
- TEVA PHARMACEUTICAL INDUSTRIES LTD - 8-K Filing
- TEVA PHARMACEUTICAL INDUSTRIES LTD - 8-K Filing
- Teva Pharmaceuticals Accelerates Growth Strategy with Branded Drugs and Biosimilars
- Teva Submits $125 Million Bid for BioXcel Assets Amid Bankruptcy
- TEVA PHARMACEUTICAL INDUSTRIES LTD - 8-K Filing
- BioXcel Therapeutics Files for Bankruptcy Just Weeks Before Key FDA Decision
- Teva Announces Offering of Senior Notes for Debt Refinancing
- Teva Submits $125M Bid for BioXcel Assets in Bankruptcy Auction
- Trump Announces New Drug Pricing Agreements With Nine Pharma Companies
- TEVA PHARMACEUTICAL INDUSTRIES LTD - 8-K Filing
- TEVA PHARMACEUTICAL INDUSTRIES LTD - 8-K Filing
- Teva Pharmaceuticals Acquires Neuroscience Assets from BioXcel Therapeutics in Up to $125M Deal
- Aurinia Pharmaceuticals and Teva Settle Patent Dispute Over LUPKYNIS
- Teva Receives FDA Priority Review for Experimental Drug Targeting Tourette Syndrome
- Teva Pharmaceutical Announces Direct Listing of Ordinary Shares on NYSE Starting September 14
- Teva Pharmaceutical Stock Surges on Q2 Results and Upcoming NYSE Listing
- Teva Pharmaceutical's Q2 Report Sparks Significant Stock Surge
- Teva Reports Mixed Q2 Results, Shares Rise on Revenue Beat and Branded Drug Growth
- Teva Pharmaceutical Reports Q2 Earnings with Growth in Innovative Medicines
- TEVA PHARMACEUTICAL INDUSTRIES LTD - 10-Q Filing
- Teva Pharmaceutical Reports Better-Than-Expected Second Quarter Revenue
- TEVA PHARMACEUTICAL INDUSTRIES LTD - 8-K Filing
- Dr. Reddy's Laboratories Reports Q1 Revenue Decline Amid Semaglutide and Lenalidomide Challenges
- Teva Pharmaceutical Industries (TEVA) Ends Seven-Session Losing Streak
- Federal Appeals Court Revives Teva's Lawsuit Against Eli Lilly Over Generic Version of Forteo
- Teva Reports Positive Austedo Data and Expands Biosimilars Portfolio
- UroGen settles patent dispute with Teva over Jelmyto
- Veeva Systems Unveils Falcon AI Platform to Enhance Drug Development Processes